These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1053 related articles for article (PubMed ID: 19223699)
1. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance]. Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699 [TBL] [Abstract][Full Text] [Related]
2. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109 [TBL] [Abstract][Full Text] [Related]
4. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750 [TBL] [Abstract][Full Text] [Related]
5. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa. Yasmin F; Akhtar N; Hameed A Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966 [TBL] [Abstract][Full Text] [Related]
6. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens]. Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503 [TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years]. Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905 [TBL] [Abstract][Full Text] [Related]
8. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977 [TBL] [Abstract][Full Text] [Related]
9. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups. Gailiene G; Pavilonis A; Kareiviene V Medicina (Kaunas); 2007; 43(1):36-42. PubMed ID: 17297282 [TBL] [Abstract][Full Text] [Related]
10. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years]. Dou Y; Zhang Q Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983 [TBL] [Abstract][Full Text] [Related]
11. [Antibiotic resistance and biofilm formation in Pseudomonas aeruginosa strains isolated from patients with urinary tract infections]. Cernohorská L; Sláviková P Epidemiol Mikrobiol Imunol; 2009 Nov; 58(4):154-7. PubMed ID: 21114003 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Tessier F; Quentin C Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845 [TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Sader HS; Huband MD; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652 [No Abstract] [Full Text] [Related]
15. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics]. Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430 [TBL] [Abstract][Full Text] [Related]
16. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966 [TBL] [Abstract][Full Text] [Related]
18. Comparison of imipenem and five other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa. Gerçeker AA; Otük G Chemotherapy; 1995; 41(5):334-6. PubMed ID: 8521734 [TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa: Evaluation of Pathogen Burden and Drug-Resistance Trends in a Tertiary Care Hospital. Saeed M; Rasheed F; Afzal RK; Hussain S; Riaz S; Ahmad A J Coll Physicians Surg Pak; 2018 Apr; 28(4):279-283. PubMed ID: 29615167 [TBL] [Abstract][Full Text] [Related]
20. Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns. Gholipourmalekabadi M; Sameni M; Hashemi A; Zamani F; Rostami A; Mozafari M Burns; 2016 Feb; 42(1):131-140. PubMed ID: 26603913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]